Shen Hongtao, Zhu Haichuan, Song Mowei, Tian Yonglu, Huang Yafei, Zheng Hui, Cao Ruiyuan, Lin Jian, Bi Zhenggang, Zhong Wu
The First Affiliated Hospital of Harbin Medical University, Harbin, China.
BMC Cancer. 2014 Aug 29;14:629. doi: 10.1186/1471-2407-14-629.
The 90-kDa heat shock protein HSP90AA1 is critical for the stability of several proteins that are important for tumor progression and thus, is a promising target for cancer therapy. Selenosemicarbazone metal complexes have been shown to possess anticancer activity through an unknown molecular mechanism.
The MTT assay, fluorescence-activated cell sorting, and fluorescent microscopy were used to analyze the mechanism of the anti-cancer activity of the selenosemicarbazone metal complexes. Additionally, RNA-seq was applied to identify transcriptional gene changes, and in turn, the signaling pathways involved in the process of 2-24a/Cu-induced cell death. Last, the expression of HSP90AA1, HSPA1A, PIM1, and AKT proteins in 2-24a/Cu-treated cells were investigated by western blot analysis.
A novel selenosemicarbazone copper complex (2-24a/Cu) efficiently induced G2/M arrest and was cytotoxic in cancer cells. 2-24a/Cu significantly induced oxidative stress in cancer cells. Interestingly, although RNA-seq revealed that the transcription of HSP90AA1 was increased in 2-24a/Cu-treated cells, western blotting showed that the expression of HSP90AA1 protein was significantly decreased in these cells. Furthermore, down-regulation of HSP90AA1 led to the degradation of its client proteins (PIM1 and AKT1), which are also cancer therapy targets.
Our results showed that 2-24a/Cu efficiently generates oxidative stress and down-regulates HSP90AA1 and its client proteins (PIM1, AKT1) in U2os and HeLa cells. These results demonstrate the potential application of this novel copper complex in cancer therapy.
90 kDa热休克蛋白HSP90AA1对几种对肿瘤进展至关重要的蛋白质的稳定性至关重要,因此,它是癌症治疗的一个有前景的靶点。硒代氨基脲金属配合物已被证明通过未知的分子机制具有抗癌活性。
采用MTT法、荧光激活细胞分选和荧光显微镜分析硒代氨基脲金属配合物的抗癌活性机制。此外,应用RNA测序来鉴定转录基因变化,进而确定参与2-24a/Cu诱导细胞死亡过程的信号通路。最后,通过蛋白质免疫印迹分析研究2-24a/Cu处理细胞中HSP90AA1、HSPA1A、PIM1和AKT蛋白的表达。
一种新型硒代氨基脲铜配合物(2-24a/Cu)能有效诱导G2/M期阻滞,并对癌细胞具有细胞毒性。2-24a/Cu显著诱导癌细胞中的氧化应激。有趣的是,尽管RNA测序显示在2-24a/Cu处理的细胞中HSP90AA1的转录增加,但蛋白质免疫印迹显示这些细胞中HSP90AA1蛋白的表达显著降低。此外,HSP90AA1的下调导致其客户蛋白(PIM1和AKT1)的降解,而这些蛋白也是癌症治疗的靶点。
我们的结果表明,2-24a/Cu在U2os和HeLa细胞中能有效产生氧化应激,并下调HSP90AA1及其客户蛋白(PIM1、AKT1)。这些结果证明了这种新型铜配合物在癌症治疗中的潜在应用。